Prototypical Stressors

Showing 801 to 825 of 874 Prototypical Stressors

ID	Prototypical Stressor Name	Associated Chemical(s): Name, CAS-RN, DTXSID	Associated AOPs

761	Tian Ma (Tall Gastrodia Tuber)		2 AOPs 487: Unknown MIE altering cholesterol metabolism leading to decreased cognition 488: Increased reactive oxygen species production leading to decreased cognitive function
768	PCB 126		2 AOPs 458: AhR activation in the liver leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals 459: AhR activation in the thyroid leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals
795	Isoproterenol		2 AOPs 554: β-adrenergic receptor agonists leading to arrhythmias. 558: Phosphodiesterase inhibition leading to heart failure
799	Milrinone		2 AOPs 554: β-adrenergic receptor agonists leading to arrhythmias. 558: Phosphodiesterase inhibition leading to heart failure
803	E-4031		2 AOPs 555: Inhibition, Ether-a-go-go (ERG) Voltage-Gated Potassium Channel leading to heart failure 556: Decreased Na/K ATPase activity leading to heart failure
811	Ivabradine		2 AOPs 560: Inhibition of Funny current (If) leading to Arrhythmias 562: HCN Channel Inhibition leading to Arrhythmias
812	Zatebradine		2 AOPs 560: Inhibition of Funny current (If) leading to Arrhythmias 562: HCN Channel Inhibition leading to Arrhythmias
868	Acenaphthene	Acenaphthene, CAS-RN: 83-32-9, DTXSID3021774	2 AOPs 645: Binding and activation of AhR lead to cardiovascular aging 646: Binding and activation of AhR/PPARγ lead to lipid metabolism disorders
869	Acenaphthylene	Acenaphthylene, CAS-RN: 208-96-8, DTXSID3023845	2 AOPs 645: Binding and activation of AhR lead to cardiovascular aging 646: Binding and activation of AhR/PPARγ lead to lipid metabolism disorders
870	Fluorene	Fluorene, CAS-RN: 86-73-7, DTXSID8024105	2 AOPs 645: Binding and activation of AhR lead to cardiovascular aging 646: Binding and activation of AhR/PPARγ lead to lipid metabolism disorders
871	Fluoranthene	Fluoranthene, CAS-RN: 206-44-0, DTXSID3024104	2 AOPs 645: Binding and activation of AhR lead to cardiovascular aging 646: Binding and activation of AhR/PPARγ lead to lipid metabolism disorders
872	Indeno(1,2,3-cd)pyrene	Indeno(1,2,3-cd)pyrene, CAS-RN: 193-39-5, DTXSID8024153	2 AOPs 645: Binding and activation of AhR lead to cardiovascular aging 646: Binding and activation of AhR/PPARγ lead to lipid metabolism disorders
873	Dibenz(a,h)anthracene	Dibenz(a,h)anthracene, CAS-RN: 53-70-3, DTXSID9020409	2 AOPs 645: Binding and activation of AhR lead to cardiovascular aging 646: Binding and activation of AhR/PPARγ lead to lipid metabolism disorders
874	Benzo(g,h,i)perylene	Benzo(g,h,i)perylene, CAS-RN: 191-24-2, DTXSID5023908	2 AOPs 645: Binding and activation of AhR lead to cardiovascular aging 646: Binding and activation of AhR/PPARγ lead to lipid metabolism disorders
4	17beta-Estradiol	17beta-Estradiol, CAS-RN: 50-28-2, DTXSID0020573	3 AOPs 314: Binding to estrogen receptor (ER)-α in immune cells leading to exacerbation of systemic lupus erythematosus (SLE) 503: Activation of uterine estrogen receptor-alfa leading to endometrial adenocarcinoma, via epigenetic modulation 504: SULT1E1 inhibition leading to uterine adenocarcinoma via increased estrogen availability at target organ level
26	Fadrozole	Fadrozole, CAS-RN: 102676-47-1, DTXSID5034141	3 AOPs 153: Aromatase Inhibition leading to Ovulation Inhibition and Decreased Fertility in Female Rats 346: Aromatase inhibition leads to male-biased sex ratio via impacts on gonad differentiation 25: Aromatase inhibition leading to reproductive dysfunction
36	Mercury	Mercury, CAS-RN: 7439-97-6, DTXSID1024172	3 AOPs 552: Inhibiton of L-Type Calcium Channels leading to heart failure via QT interval prolongation and Torsades de Pointes (TdP) 556: Decreased Na/K ATPase activity leading to heart failure 558: Phosphodiesterase inhibition leading to heart failure
46	Phenanthrene	Phenanthrene, CAS-RN: 85-01-8, DTXSID6024254	3 AOPs 644: Bulky DNA adducts leading to chromosomal aberrations and mutations 645: Binding and activation of AhR lead to cardiovascular aging 646: Binding and activation of AhR/PPARγ lead to lipid metabolism disorders
65	Di(2-ethylhexyl) phthalate	Di(2-ethylhexyl) phthalate, CAS-RN: 117-81-7, DTXSID5020607	3 AOPs 457: Succinate dehydrogenase inhibition leading to increased insulin resistance through reduction in circulating thyroxine 575: Decreased testosterone synthesis leading to increased nipple retention (NR) in male (rodent) offspring 570: Decreased testosterone synthesis leading to hypospadias in male (mammalian) offspring
145	Finasteride		3 AOPs 305: 5α-reductase inhibition leading to short anogenital distance (AGD) in male (mammalian) offspring 576: 5α-reductase inhibition leading to increased nipple retention (NR) in male (rodent) offspring 571: 5α-reductase inhibition leading to hypospadias in male (mammalian) offspring
171	Pyrethrins and Pyrethroids		3 AOPs 162: Enhanced hepatic clearance of thyroid hormones leading to thyroid follicular cell adenomas and carcinomas in the rat and mouse 442: Binding to voltage gate sodium channels during development leads to cognitive impairment 553: Inhibition of Voltage-gated sodium channels (Na⁺ channels) leading to heart failure
172	Tamoxifen	Tamoxifen, CAS-RN: 10540-29-1, DTXSID1034187	3 AOPs 165: Antiestrogen activity leading to ovarian adenomas and granular cell tumors in the mouse 440: Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia 503: Activation of uterine estrogen receptor-alfa leading to endometrial adenocarcinoma, via epigenetic modulation
191	Clofibrate	Clofibrate, CAS-RN: 637-07-0, DTXSID3020336	3 AOPs 177: Cyclooxygenase 1 (COX1) inhibition leading to renal failure and mortality 37: PPARα activation leading to hepatocellular adenomas and carcinomas in rodents 323: PPARalpha Agonism Leading to Decreased Viable Offspring via Decreased 11-Ketotestosterone
202	Fluoxetine		3 AOPs 195: 5-hydroxytryptamine transporter (5-HTT) inhibition leading to population increase 97: 5-hydroxytryptamine transporter (5-HTT; SERT) inhibition leading to population decline 203: 5-hydroxytryptamine transporter inhibition leading to decreased reproductive success and population decline
224	nanoparticles		3 AOPs 144: Endocytic lysosomal uptake leading to liver fibrosis 392: Decreased fibrinolysis and activated bradykinin system leading to hyperinflammation 451: Interaction with lung resident cell membrane components leads to lung cancer